Literature DB >> 4423775

Synergism of ICRF 159 and radiotherapy in treatment of experimental tumors.

K Hellmann, G E Murkin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4423775     DOI： 10.1002/1097-0142(197410)34:4<1033::aid-cncr2820340412>3.0.co;2-0

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  13 in total

1.  Combined razoxane and radiotherapy for melanoma brain metastases. a retrospective analysis.

Authors:  Walter Rhomberg; Helmut Eiter; Franz Boehler; Christoph Saely; Robert Strohal
Journal:  J Neurooncol       Date:  2005-09       Impact factor: 4.130

Review 2.  [Angiosarcoma of the right atrium: local control via low radiation doses and razoxane. A case report].

Authors:  W Rhomberg; M Grass
Journal:  Strahlenther Onkol       Date:  1999-03       Impact factor: 3.621

3.  Phase I clinical trial and pharmacokinetics of weekly ICRF-187 (NSC 169780) infusion in patients with solid tumors.

Authors:  C L Vogel; E Gorowski; E Davila; M Eisenberger; J Kosinski; R P Agarwal; N Savaraj
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

4.  Responses of liver metastases to radiotherapy and razoxane.

Authors:  K Hellmann; M Goold; N Higgins; R H Phillips
Journal:  J R Soc Med       Date:  1992-03       Impact factor: 5.344

5.  Antitumor effect of RA233 alone and combined with radiotherapy.

Authors:  X T Li; K Hellmann
Journal:  Clin Exp Metastasis       Date:  1983 Apr-Jun       Impact factor: 5.150

6.  Combined vindesine and razoxane shows antimetastatic activity in advanced soft tissue sarcomas.

Authors:  Walter Rhomberg; Helmut Eiter; Franz Schmid; Christoph H Saely
Journal:  Clin Exp Metastasis       Date:  2007-10-12       Impact factor: 5.150

7.  The radiation response of sarcomas by histologic subtypes: a review with special emphasis given to results achieved with razoxane.

Authors:  Walter Rhomberg
Journal:  Sarcoma       Date:  2006

8.  ICRF-159 enhancement of radiation response in combined modality therapies. I. Time/dose relationships for tumour response.

Authors:  C J Kovacs; M J Evans; L L Schenken; D R Burholt
Journal:  Br J Cancer       Date:  1979-05       Impact factor: 7.640

9.  Changes in sensitivity to radiation and ICRF 159 during the life of monolayer cultures of EMT6 tumour line.

Authors:  I W Taylor; N M Bleehen
Journal:  Br J Cancer       Date:  1977-05       Impact factor: 7.640

10.  ICRF-159 enhancement of radiation response in combined modality therapies. II. Differential responses of tumour and normal tissues.

Authors:  C J Kovacs; M J Evans; D R Burholt; L L Schenken
Journal:  Br J Cancer       Date:  1979-05       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.